PDS Biotechnology Corporation fell 12.2% on Monday, November 9, 2026, on 4,098,300 shares. No headline about PDSB came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
PDS Biotechnology Corporation (PDSB:NASDAQ) closed at $0.873 on November 13, 2026, down 10.96% on the day. The stock trades 51.3% below its 52-week high of $1.79 and 347.5% above its 52-week low of $0.195. Over the past year, it gained 3.8%. PDS Biotechnology Corporation is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, PDSB closed higher on 113 days (45%). Its best day was September 16, 2026 (+69.40%) and its worst was August 11, 2026 (-64.84%). The stock moved 10% or more in a single session 39 times. It opened at least 5% above the previous day's high 5 times.
Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. Its core objective lies in the development and commercialization of therapies for serious unmet medical conditions, especially neurological disorders in the hospital setting. The company is currently evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge uses its trademark platform known as Precisa, which enables the creation of polymer-based therapeutics capable of delivering directly to the site of injury, without affecting other areas of the body resulting in side-effects.
Find more stocks like PDSB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.